Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study-Reference-Cited by-同舟云学术

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

Published:2023-04 Issue:4 Volume:10 Page:e272-e283
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Garcia-Manero Guillermo,Goldberg Aaron D,Winer Eric S,Altman Jessica K,Fathi Amir T,Odenike Olatoyosi,Roboz Gail J,Sweet Kendra,Miller Crystal,Wennborg Anders,Hickman Denice K,Kanagal-Shamanna Rashmi,Kantarjian Hagop,Lancet Jeffrey,Komrokji Rami,Attar Eyal C,Sallman David A

Publisher

Elsevier BV

Subject

Hematology

Reference32 articles.

1. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes;Kadia;Cancer,2016

2. Genomic classification and prognosis in acute myeloid leukemia;Papaemmanuil;N Engl J Med,2016

3. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes;Sallman;Leukemia,2016

4. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes;Montalban-Bravo;Blood Adv,2020

5. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes;Bernard;Nat Med,2020

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment;Frontiers in Pharmacology;2024-08-05

2. APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells;Baghdad Science Journal;2024-08-01

3. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

4. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

5. TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment;Laboratory Medicine;2024-07-13